|
|
||||||||||||||||||||||||||||
![]() |
![]() |
|
||||||||||||||||||||||||||
|
product overview blood & research irradiators - Gammacell® 1000 / 3000
|
|
|||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||
|
Click here to download the PDF Brochure for this product. Gammacell® 3000 Elan Source Options & CDR. If unable to open this document, please Click here to Install Adobe Reader on your computer. Once you have Adobe Reader, you should be able to read any PDF document on this web site.
Graft-Versus-Host Disease Transfusion-Associated GVHD (TA-GVHD) has become a major concern in current transfusion practices for immuno-deficient and immuno-suppressed patients because of the associated high mortality rate. Immuno-suppressive therapies have not proven effective for TA-GVHD. Preventing TA-GVHD Because patient treatment of TA-GVHD is almost always ineffective, management must focus on prevention by minimizing the risk of developing the condition. Prevention has centered on reducing or inactivating transfused donor lymphocytes. The methods presently available in blood banks to physically remove T lymphocytes through washing or filtration do not provide effective prophyl-axis against TA-GVHD. Inactivation of transfused lymphocytes with the use of gamma irradiation of blood components remains the most efficient method for inhibiting lymphocyte blast transformation and mitotic activity and hence preventing TA-GVHD. Features
Virtually all cellular blood components have been implicated in reported cases of TA-GVHD. The syndrome has developed after transfusion of whole blood, red blood cells, platelets, fresh (non-frozen) plasma and leukocytes harvested from both normal donors and donors with chronic myelocytic leukemia. Current medical practice and the AABB recommend using irradiated blood for immuno-incompetent or immuno-compromised patients. |
|
|||||||||||||||||||||||||||
|
© 2008-2012
Best Theratronics Ltd., a member of
TeamBest™ |
|
|||||||||||||||||||||||||||